The present specification relates to an adamantanecarboxylic acid benzyl amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, and a skin whitening composition comprising the same as an active ingredient. Specifically, the compound, according to the present specification, is a compound having a novel structure having adamantanecarboxylic acid bound to an amine compound, and exhibits a skin whitening effect by inhibiting the production of melanin, and thus may be used in various ways as a pharmaceutical composition, a cosmetic composition or a skin preparation for external use.

The present specification relates to an adamantanecarboxylic acid benzyl amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, and a skin whitening composition comprising the same as an active ingredient. Specifically, the compound, according to the present specification, is a compound having a novel structure having adamantanecarboxylic acid bound to an amine compound, and exhibits a skin whitening effect by inhibiting the production of melanin, and thus may be used in various ways as a pharmaceutical composition, a cosmetic composition or a skin preparation for external use.

The present disclosure relates to compounds of Formula (I):

##STR00001##

or pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing diseases, disorders, or conditions (e.g., associated with mitochondria).

The present disclosure relates to compounds of Formula (I):

##STR00001##

or pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing diseases, disorders, or conditions (e.g., associated with mitochondria).

RhlR modulators including agonist and antagonists which are useful for modulating QS phenotypes in Gram-negative bacteria. Certain compounds of general formula A-W-HG having various carbocyclic ad heterocyclic head groups (HG) and various tail groups (A), where W is CONH, SO.sub.2NH, CONHCH.sub.2, or SO.sub.2NHCH.sub.2 are RhlR agonists or antagonists. The compounds are useful in methods of modulating quorum sensing in Gram-negative bacteria, particularly in Pseudomonas. Compositions including certain RhlR modulators are useful for decreasing the virulence of Gram-negative bacteria. Pharmaceutical compositions comprising certain RhlR modulators are useful for treatment of infections of Gram-negative bacteria.

The invention relates to metabolites of cabozantinib (I) as well as uses thereof. ##STR00001##

The invention relates to metabolites of cabozantinib (I) as well as uses thereof. ##STR00001##

The invention relates to active ingredient compositions comprising a) one or more active substances, and b) one or more N-alkenoyl-N-alkylglucamides of the formula I

##STR00001##

in which R1 is a linear or branched alkenyl group which has 7 to 16 carbon atoms and has a non-terminal double bond or a plurality of conjugated or non-conjugated double bonds, and R2 is an alkyl group having 1 to 4 carbon atoms.

The compounds of formula I can be used for reducing drift and for improving wettability when appyling active ingredient compositions.

The invention relates to active ingredient compositions comprising a) one or more active substances, and b) one or more N-alkenoyl-N-alkylglucamides of the formula I

##STR00001##

in which R1 is a linear or branched alkenyl group which has 7 to 16 carbon atoms and has a non-terminal double bond or a plurality of conjugated or non-conjugated double bonds, and R2 is an alkyl group having 1 to 4 carbon atoms.

The compounds of formula I can be used for reducing drift and for improving wettability when appyling active ingredient compositions.

A method for detecting phospholipase D (PLD) activity in a cell, comprising: (i) stimulating endogenous PLD in said cell for said PLD to catalyze a transphosphatidylation reaction between phosphatidylcholine or a derivative thereof and an exogenous functionalized alcohol to form a phosphatidyl alcohol, wherein the functionalized alcohol possesses a first functional group that can react with and form a bond to a functionalized detectable label having a second functional group reactive with the first functional group, and said phosphatidyl alcohol contains said first functional group in available form; (ii) reacting said phosphatidyl alcohol with said functionalized detectable label under conditions where said functionalized detectable label reacts, via its second functional group, with the first functional group to form a linkage between said detectable label and said phosphatidyl alcohol so as to form a labeled phosphatidyl alcohol containing said detectable label; and (iii) detecting said labeled phosphatidyl alcohol.